2. GPCR/G Protein Neuronal Signaling
  3. Adrenergic Receptor
  4. Dobutamine

Dobutamine is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine can increase cardiac output and correct hypoperfusion.

For research use only. We do not sell to patients.

CAS No. : 34368-04-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Dobutamine:

Dobutamine Related Antibodies

Top Publications Citing Use of Products

    Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656.  [Abstract]

    Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) decreased IR-induced cell apoptosis. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-downcells with IR treatment.

    Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656.  [Abstract]

    Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) decreased IR-induced cell apoptosis. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-down cells with IR treatment.

    Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656.  [Abstract]

    Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) showed the percentages of G1 cells in IRtreated control and BRCA1 knock-down A2780 cells decreased to 44.32 and 43.03%, respectively, suggesting that cAMP terminated the cell cycle arrest caused by DNA damage. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-down cells with IR treatment.

    Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656.  [Abstract]

    Dobutamine hydrochloride (dobutamine; 10 μM) treated BRCA1 knock-down A2780 cells could inhibited the proliferation of the CD8+ T cells.

    Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656.  [Abstract]

    Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) showed weaker BAX signals in the IR-irradiated control and BRCA1 knockdown A2780 cells, and 13.7 and 14.5% of cancer cells were BAX positive, respectively.

    Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656.  [Abstract]

    Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) decreased the protein expression of BAX and cleaved caspase-3 in the IR-irradiated control and BRCA1 knockdown A2780 cells.

    Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656.  [Abstract]

    Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) decreased the protein expression of p53 in the IR-irradiated BRCA1 knockdown A2780 cells.

    View All Adrenergic Receptor Isoform Specific Products:

    View All Isoforms
    α adrenergic receptor β adrenergic receptor

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Dobutamine is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine can increase cardiac output and correct hypoperfusion[1][2][3][4].

    IC50 & Target

    α adrenergic receptor

     

    β adrenergic receptor

     

    Cellular Effect
    Cell Line Type Value Description References
    HEK293 IC50
    4.17 μM
    Compound: Dobutamine
    Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
    Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
    		[PMID: 28230985]
    Hepatocyte IC50
    3.7 nM
    Compound: Dobutamine
    Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs
    Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs
    		[PMID: 18212104]
    In Vivo

    Dobutamine has a rapid onset of action and a short half-life [2].
    Dobutamine (0.15-20 mg/kg; i.p.) results in subsequent increase in the left ventricular function and heart rate acceleration with an increasing dose in wildtype mice[3].
    Dobutamine results in significant inotropic, lusitropic, and chronotropic cardiac response with a high dose in wildtype mice[3].
    Low doses of Dobutamine significantly increases inotropic and lusitropic cardiac performance without chronotropic changes in the Tgαq*44 mice[3].
    Dobutamine increases heart rate only after high doses, but then inotropic and lusitropic cardiac functional reserve is lost[3].
    Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Tgαq*44 mice (heart failure models)[3]
    Dosage: 0.15 mg/kg, 0.5 mg/kg as a low dose, 1.5 mg/kg, 5 mg/kg, 20 mg/kg as a high dose
    Administration: Intraperitoneal injection
    Result: Induced different response in cardiac function on a low and high dose in mice with with heart failure.
    Clinical Trial
    Molecular Weight

    301.38

    Formula

    C18H23NO3
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    OC1=CC=C(CCNC(C)CCC2=CC=C(O)C=C2)C=C1O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (331.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.3181 mL 16.5904 mL 33.1807 mL
    5 mM 0.6636 mL 3.3181 mL 6.6361 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (16.59 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (16.59 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.3181 mL 16.5904 mL 33.1807 mL 82.9518 mL
    5 mM 0.6636 mL 3.3181 mL 6.6361 mL 16.5904 mL
    10 mM 0.3318 mL 1.6590 mL 3.3181 mL 8.2952 mL
    15 mM 0.2212 mL 1.1060 mL 2.2120 mL 5.5301 mL
    20 mM 0.1659 mL 0.8295 mL 1.6590 mL 4.1476 mL
    25 mM 0.1327 mL 0.6636 mL 1.3272 mL 3.3181 mL
    30 mM 0.1106 mL 0.5530 mL 1.1060 mL 2.7651 mL
    40 mM 0.0830 mL 0.4148 mL 0.8295 mL 2.0738 mL
    50 mM 0.0664 mL 0.3318 mL 0.6636 mL 1.6590 mL
    60 mM 0.0553 mL 0.2765 mL 0.5530 mL 1.3825 mL
    80 mM 0.0415 mL 0.2074 mL 0.4148 mL 1.0369 mL
    100 mM 0.0332 mL 0.1659 mL 0.3318 mL 0.8295 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Dobutamine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Dobutamine34368-04-2Adrenergic ReceptorBeta Receptorheart failurecardiogenicshocksympathomimeticdrugInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Dobutamine
    Cat. No.:
    HY-15746A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.